DaVita/DVA

$129.96

-0.35%
-
1D1W1MYTD1YMAX

About DaVita

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.

Ticker

DVA

Sector

Healthcare

Trading on

NYSE

Industry

Healthcare Facilities

CEO

Javier Rodriguez

Employees

70,000

Headquarters

Denver, United States

DaVita Metrics

BasicAdvanced
$11.44B
Market cap
17.60
P/E ratio
$7.41
EPS
1.06
Beta
-
Dividend rate
$11.44B
1.05616
$141.54
$71.51
850.14K
1.188
1.133
782.914
794.589
18.622
4.77%
5.66%
78.21%
7.55%
17.604
0.942
10.969
7.671
4.57%
31.43%
1.67%
5.13%

What the Analysts think about DaVita

Analyst Ratings

Majority rating from 8 analysts.
Hold

Price Targets

Average projection from 7 analysts.
1.57% upside
High $145.00
Low $114.00
$129.96
Current price
$132.00
Average price target

DaVita Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
4.78% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.15B
0.78%
Net income
$150.6M
-38.93%
Profit margin
4.78%
-39.49%

DaVita Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 1.67%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$1.25
$1.91
$2.62
$1.62
-
Expected
$1.15
$1.69
$2.02
$1.59
$1.95
Surprise
9.17%
12.8%
29.92%
1.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for DaVita stock?

DaVita (DVA) has a market cap of $11.44B as of April 16, 2024.

What is the P/E ratio for DaVita stock?

The price to earnings (P/E) ratio for DaVita (DVA) stock is 17.6 as of April 16, 2024.

Does DaVita stock pay dividends?

No, DaVita (DVA) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next DaVita dividend payment date?

DaVita (DVA) stock does not pay dividends to its shareholders.

What is the beta indicator for DaVita?

DaVita (DVA) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the DaVita stock price target?

The target price for DaVita (DVA) stock is $132, which is 1.57% above the current price of $129.96. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell DaVita stock

Buy or sell DaVita stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing